

Keryx Biopharmaceuticals Inc (KERX) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/K32245A3B91EN.html
Date:	May 3, 2018
Pages:	44
Price:	US\$ 125.00
ID:	K32245A3B91EN

Keryx Biopharmaceuticals Inc (KERX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Keryx Biopharmaceuticals Inc (Keryx) develops and commercializes new therapies for the treatment of renal disease. The company's lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based phosphate binder, which helps lower the amount of phosphate in human blood. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This product is also marketed in Japan under the brand name Riona through Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd, and in Europe as Fexeric (ferric citrate coordination complex). The company has subsidiaries and offices in Israel, the US, and the UK. Keryx is headquartered in New York City, New York, the US.

Keryx Biopharmaceuticals Inc Key Recent Developments

Apr 30,2018: Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue

Feb 07,2018: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results
Nov 07,2017: Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results
Sep 13,2017: Keryx Biopharmaceuticals Announces Changes to its Board of Directors
Jul 27,2017: Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

Keryx Biopharmaceuticals Inc - Key Facts
Keryx Biopharmaceuticals Inc - Key Employees
Keryx Biopharmaceuticals Inc - Key Employee Biographies
Keryx Biopharmaceuticals Inc - Major Products and Services
Keryx Biopharmaceuticals Inc - History
Keryx Biopharmaceuticals Inc - Company Statement
Keryx Biopharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

Keryx Biopharmaceuticals Inc - Business Description

Keryx Biopharmaceuticals Inc - SWOT Analysis

SWOT Analysis - Overview

Keryx Biopharmaceuticals Inc - Strengths

Keryx Biopharmaceuticals Inc - Weaknesses

Keryx Biopharmaceuticals Inc - Opportunities

Keryx Biopharmaceuticals Inc - Threats

Keryx Biopharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018

Keryx Biopharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Apr 30, 2018: Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue

Feb 07, 2018: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results

Nov 07, 2017: Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results

Sep 13, 2017: Keryx Biopharmaceuticals Announces Changes to its Board of Directors

Sep 13, 2017: Keryx Biopharmaceuticals Announces Changes to its Board of Directors

Jul 27, 2017: Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance

May 04, 2017: Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results

Mar 01, 2017: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

LIST OF TABLES

Keryx Biopharmaceuticals Inc, Key Facts

Keryx Biopharmaceuticals Inc, Key Employees

Keryx Biopharmaceuticals Inc, Key Employee Biographies

Keryx Biopharmaceuticals Inc, Major Products and Services

Keryx Biopharmaceuticals Inc, History
Keryx Biopharmaceuticals Inc, Subsidiaries
Keryx Biopharmaceuticals Inc, Key Competitors
Keryx Biopharmaceuticals Inc, Ratios based on current share price
Keryx Biopharmaceuticals Inc, Annual Ratios
Keryx Biopharmaceuticals Inc, Annual Ratios (Cont.1)
Keryx Biopharmaceuticals Inc, Interim Ratios
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Keryx Biopharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Keryx Biopharmaceuticals Inc, Performance Chart (2013 - 2017)
Keryx Biopharmaceuticals Inc, Ratio Charts
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Shire Plc
Roxane Laboratories Inc
GlaxoSmithKline LLC
Genzyme Corp
Fresenius Medical Care AG & Co KGaA
Akebia Therapeutics Inc

I would like to order:

Product name: Keryx Biopharmaceuticals Inc (KERX) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/K32245A3B91EN.html>
Product ID: K32245A3B91EN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/K32245A3B91EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**